ResMed Inc. (RMD) Stock Analysis
Is RMD a good investment?
ResMed Inc. (RMD) has a Plutrex AI rating of 72.0/100 as of October 05, 2026, indicating a Buy consensus. The stock is halal-compliant per AAOIFI standards. Key strength: Unmatched profitability fortress: Operating margin 30.9% (2.2x industry average of 13.83%), net margin 26.9% (5x industry average of 5.27%), ROE 24.3% (3.5x industry average 6.90%) — all achieved with near-zero debt (D/E 0.08 vs. industry 0.54). These are structural moat characteristics, not cyclical outperformance.. Main concern: Competitive threats are real and emerging: The headline 'Is This the Right Time to Retain Resmed Stock in Your Portfolio?' captures three converging risks — GLP-1 weight-loss drugs potentially reducing sleep apnea prevalence, Philips returning to the US CPAP market (the most credible threat, potentially eroding RMD's dominant market share gained during Philips' recall crisis), and reimbursement changes that could compress device economics. The Pomerantz Law Firm investigation ('INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RMD') adds regulatory/legal overhang that could weigh on sentiment..
Investment Summary
ResMed (RMD) at $218.89 is a world-class medical device compounder caught in a classic 'wonderful company, full price' dilemma. The fundamentals are genuinely elite: gross margin of 60.2% (vs. industry avg 44.25%), operating margin of 30.9% (vs. industry avg 13.83%), net margin of 26.9% (vs. industry avg 5.27%), ROE of 24.3% (vs. industry avg 6.90%) — all achieved with debt-to-equity of just 0.08 versus industry average of 0.54. Free cash flow of $2.89 billion is extraordinary. However, the valuation-growth mismatch is the central tension: PEG of 2.27 against 9.2% forward 5-year EPS growth creates a ~20-35% premium to intrinsic value on a DCF basis ($185-$210 fair value range). Importantly, relative to industry peers, RMD's PEG of 2.27 is 41.9% BELOW the industry average PEG of 3.90, which partially rehabilitates the valuation concern — RMD is expensive vs. its own growth rate but cheap vs. peers. Management's guidance of 12-14% EPS growth (headline: 'ResMed Targets 12%-14% EPS Growth as GLP-1 Patients Lift Sleep Therapy Demand') would improve the PEG to ~1.7-1.8x if achieved, which is fair value territory. Three genuine business risks — GLP-1 sleep apnea pills, Philips US market reentry, and reimbursement changes — create near-term uncertainty. A Pomerantz law firm investigation ('INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors') adds modest headline risk. Net verdict: Hold/Buy on pullback — exceptional quality deserves a position, but not at the current stretched price.
Key Strengths
- Unmatched profitability fortress: Operating margin 30.9% (2.2x industry average of 13.83%), net margin 26.9% (5x industry average of 5.27%), ROE 24.3% (3.5x industry average 6.90%) — all achieved with near-zero debt (D/E 0.08 vs. industry 0.54). These are structural moat characteristics, not cyclical outperformance.
- Cash machine with pristine balance sheet: $2.89B FCF and $1.47B cash with virtually zero debt create a self-funding compounding engine. This eliminates financing risk and funds R&D, buybacks, and M&A without dilution — the 'EPS growth via buybacks' pattern (17% EPS vs 2.4% earnings growth) can continue sustainably.
- Relative valuation discount to peers: PEG of 2.27 is 41.9% below the industry average PEG of 3.90, and PE of 20.97x is 41.3% below industry average of 35.72x. Management's 12-14% EPS growth target (vs. analyst consensus of 9.9%) would compress the PEG to ~1.7-1.8x — a potential re-rating catalyst if achieved.
Key Concerns
- Competitive threats are real and emerging: The headline 'Is This the Right Time to Retain Resmed Stock in Your Portfolio?' captures three converging risks — GLP-1 weight-loss drugs potentially reducing sleep apnea prevalence, Philips returning to the US CPAP market (the most credible threat, potentially eroding RMD's dominant market share gained during Philips' recall crisis), and reimbursement changes that could compress device economics. The Pomerantz Law Firm investigation ('INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RMD') adds regulatory/legal overhang that could weigh on sentiment.
- Valuation-growth mismatch at current price: PEG of 2.27 vs. analyst consensus forward EPS growth of 9.2% implies ~20-35% premium to fair value on a growth-adjusted basis. DCF fair value of $185-$210 puts current price $9-$34 above intrinsic value. With analyst consensus target of $242.75 implying only 10.9% upside (equal to earnings growth — no multiple expansion), the risk/reward at $218.89 is insufficient unless management's 12-14% EPS growth guidance proves accurate.
Plutrex 10-Factor AI Breakdown
Fundamental Analysis
RMD's profitability is best-in-class across every metric. Gross margin of 60.2% (vs. industry 44.25%, +36.2% premium) reflects pricing power from its connected health/software ecosystem. Operating margin of 30.9% is more than double the industry average of 13.83%, demonstrating extraordinary operational leverage. Net margin of 26.9% is nearly 5x the industry average of 5.27% — the most dramatic absolute outperformance in the peer set. ROE of 24.3% vs. industry 6.90% (+251.5%) is generated without leverage (D/E of 0.08 vs. industry 0.54), confirming genuine business quality. Cash position of $1.47B and FCF of $2.89B underpin a fortress balance sheet. The growth picture is more sobering: forward 1-year EPS growth of 9.95% and 5-year EPS growth of 9.24% lag the industry average of 12.05-12.35%. Historical YoY earnings growth of just 2.4% vs. EPS growth of 17.0% signals buybacks are masking slower absolute profit expansion — a concern for forward estimates. On valuation: PE of 20.97x vs. industry 35.72x (41.3% discount to peers) appears attractive, but the PEG of 2.27 against 9.2% growth signals the stock is expensive relative to its OWN growth trajectory. DCF analysis using 9.2% growth, 4% terminal, 9% discount rate implies fair value of $185-$210, placing current price ~4-18% above intrinsic value. Analyst consensus target of $242.75 implies only 10.9% upside — returns limited to earnings growth, no multiple expansion expected. Additional metrics: PE Ratio: 20.97
News Sentiment
ResMed is navigating a pivotal moment where its remarkable business performance meets a fresh wave of competitive and regulatory challenges. The sleep device giant recently set ambitious targets — management is projecting 12% to 14% earnings-per-share growth, fueled by an unexpected tailwind: GLP-1 weight-loss drugs like Ozempic are actually bringing new patients into sleep therapy rather than eliminating the need for it. That's a significant positive spin on what many investors feared would be an existential threat. But not everyone is convinced the company is out of the woods. Three distinct risks are converging: rival Philips is making its comeback in the U.S. CPAP market after a massive recall crisis that handed ResMed years of near-monopoly advantage; sleep apnea pill research is advancing; and insurance reimbursement changes loom on the horizon. Adding to investor unease, the Pomerantz Law Firm announced it is investigating ResMed on behalf of investors — a development that raises questions about past financial disclosures, though no conclusions have been reached. Despite these headwinds, ResMed continues to appear on curated lists of top dividend growth stocks, and analysts covering the company maintain a consensus price target of $242.75, about 11% above current levels. The bottom line for everyday investors: ResMed is a financially bulletproof company with world-class margins and no meaningful debt, but competition is returning and the stock's current price already reflects most of the good news.
Risk Assessment
PRIMARY RISK: Philips US market reentry is the most material near-term threat. RMD benefited enormously from Philips' recall-driven exit from the CPAP market, gaining substantial market share. As Philips rebuilds its US presence, RMD faces revenue headwinds in its core device segment. This could pressure both revenue growth (already below-average at 8.6%) and operating margin as competitive pricing intensifies. SECONDARY RISK: GLP-1 drugs (Ozempic/Wegovy) reducing sleep apnea incidence is a longer-term structural concern, though management appears to be reframing GLP-1 users as new sleep therapy patients ('GLP-1 Patients Lift Sleep Therapy Demand'), which is strategically sound but unproven at scale. LEGAL RISK: Pomerantz Law Firm investigation creates uncertainty around financial reporting integrity — this is a headline risk that requires monitoring but is not yet confirmed as a material event. REIMBURSEMENT RISK: CMS reimbursement changes to CPAP/sleep therapy could structurally alter device economics. MITIGATION: RMD's $2.89B FCF, zero debt, and software/connected health revenue diversification provide substantial downside cushion. A 15% drawdown from current levels (~$186) would represent an attractive entry with adequate margin of safety, at which point PEG falls to approximately 1.9x.
Related Halal Stocks
Related Stocks
Frequently Asked Questions
Is RMD a halal stock?
Yes, ResMed Inc. (RMD) is halal-compliant per AAOIFI standards as of the latest quarterly review.
What is Plutrex's AI rating for RMD?
ResMed Inc. (RMD) has a Plutrex AI rating of 72.0/100 with a Buy consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.
Is RMD a good investment?
According to Plutrex AI, RMD has a Buy rating (72.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.
How can I invest in RMD?
US stocks like RMD can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. Plutrex provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.
What are the main risks of investing in RMD?
Plutrex AI identifies the main risks for RMD by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.